Advicenne Stock

Advicenne P/B

The P/B (Price-to-Book Ratio) of Advicenne (ALDVI.PA) as of Aug 10, 2026 is -1.60. In the previous year, P/B (Price-to-Book Ratio) was -2.41 — a change of -33.89% (higher).

P/B

-1.60

YoY

-33.89%

Last updated:

P/B (Price-to-Book Ratio) of Advicenne is 2026 -1.60 . P/B (Price-to-Book Ratio) of Advicenne was 2025 -2.41 . It decreases by -33.89% higher compared to the previous year.
Access this data via the Eulerpool API

Advicenne Stock analysis

What does Advicenne do? Advicenne SA is a French pharmaceutical company specializing in the development of medications for rare and chronic diseases. The company was founded in 2007 by Dr. Luc-André Granier and is headquartered in Nîmes, France. Business model Advicenne develops its products based on proven technologies in the pharmaceutical industry. The company specializes in the development of medications for rare and chronic diseases, particularly for patients with kidney and metabolic disorders. The company implements a customer-oriented development strategy and is committed to close collaboration with doctors and patients. Advicenne has entered into various partnerships and licensing agreements with other pharmaceutical companies to distribute and further develop its products and technologies worldwide. Divisions Advicenne operates in various business areas, including the development of medications for kidney and metabolic disorders, as well as the marketing of products for patients with chronic diseases. Product portfolio The company currently offers three products: 1. Sibnayal: Sibnayal is a medication for the treatment of kidney diseases. It has been developed to prevent the disease-related loss of potassium in patients with kidney failure. The medication is currently approved for use in a clinical trial. 2. ADV7103: ADV7103 is a medication for the treatment of metabolic disorders. It has been developed to help patients with metabolic disorders such as phenylketonuria (PKU) and hypervalinemia (HV). The medication is currently approved under the name Orladeyo™ and is marketed in collaboration with Daiichi Sankyo Company, Limited. 3. ADV6209: ADV6209 is a medication for the treatment of chronic pain. It is targeted at patients who have not found sufficient pain relief due to chronic pain. The medication is currently in phase II of clinical trials. Advicenne has made significant investments in the development of innovative medications in recent years and has expanded its product pipeline to improve the therapeutic options for patients with rare and chronic diseases. Conclusion Advicenne is an emerging company in the pharmaceutical industry that focuses on the development of medications for rare and chronic diseases. The company aims to improve the lives of patients with its therapies and is committed to close collaboration with doctors and patients. Advicenne has already brought several promising products to market and continues to heavily invest in research and development to improve the therapeutic options for patients with rare and chronic diseases. Advicenne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Advicenne stock

P/B (Price-to-Book Ratio) of Advicenne is -1.60 in 2026.

P/B (Price-to-Book Ratio) of Advicenne changed from -2.41 to -1.60, representing a -33.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Advicenne since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Advicenne with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Advicenne

All Key Metrics — Advicenne